Atara Biotherapeutics
ATRA
53 hedge funds and large institutions have $462M invested in Atara Biotherapeutics in 2015 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 8 reducing their positions, and 3 closing their positions.
603% more capital inflows, than outflows
Capital inflows: $139M | Capital outflows: $19.7M
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
225% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 8
36% more funds holding
Funds holding: 39 → 53 (+14)
18.47% more ownership
Funds ownership: 27.61% → 46.08% (+18%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baupost Group
Boston,
Massachusetts
|
+$59.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.9M |
| 3 |
Neuberger Berman Group
New York
|
+$10.7M |
| 4 |
Jennison Associates
New York
|
+$7.96M |
| 5 |
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.3M |
| 2 |
Goldman Sachs
New York
|
-$1.41M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$342K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$246K |
| 5 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$228K |
ATRA Hedge Fund Activity: Q1 2015 in Review
53 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2015, worth a combined $462M — up 168% from $172M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ATRA positions and 3 closed out — a net gain of 14 holders — while 26 added to existing stakes and 8 trimmed.
The largest buyer was Baupost Group, adding an estimated $59.9M. The largest seller was Fidelity Investments, cutting an estimated $17.3M.
- 53 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2015, up from 39 in Q4 2014.
- Funds reported $462M of Atara Biotherapeutics stock for Q1 2015, up 168% quarter-over-quarter.
- 17 funds opened new Atara Biotherapeutics positions in Q1 2015 and 3 closed out, a net change of +14 holders.
- The largest Atara Biotherapeutics buyer in Q1 2015 was Baupost Group, an estimated $59.9M added.
- The largest Atara Biotherapeutics seller in Q1 2015 was Fidelity Investments, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2015.